Cost and cost-effectiveness of antiretroviral therapy for HIV infection in Singapore

International Journal of STD and AIDS

Volumn 17, Issue 10, 2006, Pages 699-705

  Paton, Nicholas I ^a,d   Chapman, Chere A T ^a   Sangeetha, S ^a   Mandalia, Sundhiya ^a,b   Bellamy, Richard ^a   Beck, Eduard J ^b,c  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c MCGILL UNIVERSITY   (Canada)

^d MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

Antiretroviral therapy; Cost effectiveness; HIV infection; Life year gained

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG UTILIZATION; FEMALE; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; SINGAPORE;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COSTS AND COST ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HOSPITALS; HUMANS; MALE; QUALITY-ADJUSTED LIFE YEARS; SINGAPORE; TREATMENT OUTCOME;

EID: 33750271698     PISSN: 09564624     EISSN: 09564624     Source Type: Journal    
DOI: 10.1258/095646206780071081     Document Type: Article

References (19)

1. Beck EJ, Miners AH. Effectiveness and efficiency in the delivery of HIV services: economic and related considerations. In: Gazzard B, Johnson M, Miles A, eds. The Effective Management of HIV Disease. London: Aesculapius Medical Press, 2001;113-38
2. Beck EJ, Miners AH, Tolley K. The cost of HIV treatment and care. A global review. Pharmacoeconomics 2001;19:13-39
3. Beck EJ, Mandalia S, Williams I, et al. Decreased morbidity and use of hospital services in English HIV-infected individuals with increased uptake of anti-retroviral therapy 1996-1997. National Prospective Monitoring System Steering Group. AIDS 1999;13:2157-64
4. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001;344:817-23
5. Keiser P, Nassar N, Kvanli MB, Turner D, Smith JW, Skiest D. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs. J Acquir Immune Defic Syndr 2001;27:14-19
6. Miners AH, Sabin CA, Trueman P, et al. Assessing the cost-effectiveness of HAART for adults with HIV in England. HIV Med 2001;2:52-8
7. Lim MK. Health care systems in transition II. Singapore, Part I. An overview of health care systems in Singapore. J Publ Health Med 1998;20:16-22
8. Harling G, Wood R, Beck EJ. Efficiency of interventions in HIV infection, 1994-2004. Dis Manage Health Outcomes 2005;13:371-94
9. Bellamy R, Sangeetha S, Paton N. Causes of death among patients with HIV infection in Singapore from 1985 to 2001: results from the Singapore HIV Observational Cohort Study. HIV Med 2004;5:289-95
10. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR CDC Surveill Summ 1987;3S-14S
11. Beck EJ, Tolley K, Power A, et al. The use and cost of HIV service provision in England in 1996. National Prospective Monitoring System (NPMS) Steering Group and NPMS Working Party on Costs. Pharmacoeconomics 1998;14:639-52
12. Beck EJ, Mandalia S, Gaudreault M, et al. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001. AIDS 2004;18:2411-18
13. Garber AM. Advances in cost-effectiveness analysis of health interventions. In: Culyer AJ, Newhouse JP, eds. Handbook of Health Economics. Amsterdam: Elsevier, 2000;188-221
14. Statistics Singapore. KeyStats - Selected Historical Data - Per Capita GDP at Current Market Prices. Singapore: Statistics Singapore. Available at [www.singstat.gov.sg/keystats/hist/gdp.html] Accessed 26 May 2006
15. Paton NI, Chapman CA, Chan SP, et al. Validation of the Medical Outcomes Study HIV Health Survey as a measure of quality of life in HIV-infected patients in Singapore. Int J STD AIDS 2002;13:456-61
16. Paton NI, Earnest A, Ng YM, Karim F, Aboulhab J. Lipodystrophy in a cohort of human immunodeficiency virus-infected Asian patients: prevalence, associated factors, and psychological impact. Clin Infect Dis 2002;35:1244-9
17. Beck EJ, Beecham J, Mandalia S, et al. What is the cost of getting the price wrong? J Publ Health Med 1999;21:311-17
18. Mullins CD, Whitelaw G, Cooke JL, Beck EJ. Indirect cost of HIV infection in England. Clin Ther 2000;22:1333-45
19. WHO. WHO Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment for a Public Health Approach, 2003 revision. Geneva: WHO, 2004